Trump’s Healthcare Order: Pharma Wins, Medicare Loses
Trump recently signed a healthcare executive order ostensibly aimed at reducing healthcare costs. However, a closer look reveals that this order, rather than benefiting the average American, appears to primarily serve the interests of pharmaceutical companies. One of the order’s key provisions seems to involve removing or delaying the ability of Medicare to negotiate lower drug prices.
This action directly contradicts previous efforts to curb prescription drug costs, prompting criticism that this executive order effectively prevents Medicare from negotiating prices until medications have been on the market for a significantly longer period. This delay could allow pharmaceutical companies to maintain higher prices for extended periods, generating considerable profits.… Continue reading
Matt Underwood